Investigates Improvement in Vision Following Switching From Avastin and Macugen Over to Lucentis

Completed

Conditions studied: Wet AMD

In brief

The purpose of this study is to determine whether people who have received intermittent anti-VEGF therapy have an improvement in vision after being switched to monthly injections of Lucentis.

Key facts

Study ID

NCT00804934

Run by

Retina Institute of Hawaii

People needed

100

Starts

2008-02-01

Expected to finish

2009-01-01

Last updated by the study team

2012-05-28

Who can join

Age: any. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Ability to provide written informed consent and comply with study assessments for the full duration of the study
• Age greater then and equal 50 years
• Patients with active neovascular AMD
• Received at least 3 treatments with anti-VEGF therapy (bevacizumab or pegaptanib or ranibizumab) in the last 24 months
• If the patient has bilateral disease and qualifies for the study, both eyes may be included

You may not qualify if…

• Subjects who meet any of the following criteria will be excluded from this study:
• Pregnancy or lactation
• Premenopausal women not using adequate contraception.
• Participation in another simultaneous medical investigation

Where it is running

• Retina Institute of Hawaii — Honolulu, Hawaii, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.